Mandating masks was associated with a decrease in daily COVID-19 case and death growth rates within 20 days of implementation. Allowing on-premises restaurant dining was associated with an increase in daily COVID-19 case growth rates 41–100 days after implementation and an increase in daily death growth rates 61–100 days after implementation. Mask mandates and restricting any on-premises dining at restaurants can help limit community transmission of COVID-19 and reduce case and death growth rates. These findings can inform public policies to reduce community spread of COVID-19. Caveat: see table 2
The results showed a positive association between COVID-19 deaths and IVR (influenza vaccine rate) of people ≥65 years-old. There is a significant increase in COVID-19 deaths from eastern to western regions in the world. Further exploration is needed to explain these findings, and additional work on this line of research may lead to prevention of deaths associated with COVID-19.
The infection fatality rate of COVID-19 can vary substantially across different locations and this may reflect differences in population age structure and casemix of infected and deceased patients and other factors. The inferred infection fatality rates tended to be much lower than estimates made earlier in the pandemic.
Re: Lack of “Independent” Members on the Data and Safety Monitoring Boards for COVID-19 Vaccines Currently in Phase III Trials in the United States.
The Centers for Disease Control (CDC) asserts that vaccines and vaccine ingredients have been disproven as potential causes of autism. Statements by the CDC are generic and encompass all vaccines and vaccine ingredients. [However,] these statements are not supported by available science. The CDC’s evidence supporting these statements is limited to the MMR vaccine (Taylor 2014), thimerosal preservative (Taylor 2014) and vaccine antigen exposure (DeStefano 2013).
With so many vaccines using an aluminum adjuvant, the National Institutes of Health (NIH) must have human or animal studies on record to establish the safety of injecting infants and children with aluminum hydroxide, aluminum phosphate or amorphous aluminum hydroxyphosphate sulfate. Right?
Human exposure to aluminium is burgeoning with significant implications for human health. Aluminium based adjuvants [ABAs] are effective and cheap but are they safe? Confirmation of their safety remains to be addressed and will only come from further research on their biological activities at injection sites and beyond. All ABAs currently in use in vaccination and sub-cutaneous immunotherapy require further validation of their safety... Burgeoning knowledge regarding the biological activities of ABAs now dictates that their safety should be evaluated independently of their presence in vaccine formulations.
In furtherance of its mission and in order to respond to the inquiries it has received, Plaintiff made a number of requests to NIH pursuant to the Freedom of Information Act (5 U.S.C. §552, as amended) (“FOIA”) for documents regarding COVID-19 and a potential COVID-19 vaccine, including a request for “all safety and efficacy data and information regarding mRNA1273, including from the Phase I clinical trial of this experimental vaccine.” While NIH granted expedited processing for this request, NIH has failed to further respond to this and all the other related requests submitted by ICAN as required under FOIA.
Has the CDC ever conducted a safety study for the health outcomes of vaccinated children compared to un-vaccinated children? Nope! At least not as of July 2020.
Americans are riveted and captured by fear at the moment. We are not held down by the virus as much as we’re being held down by the spider web of fear. That spider web is all around us and it’s constricting us and it’s draining the lifeblood of the American people, American society, and American economy.
|
Archives
March 2021
|